![(3E)-N,N-Dimethyl-3-[2-(Trifluoromethyl)Thioxanthen-9-Ylidene]Propan-1-Amine Chloride](https://static.cymitquimica.com/products/3D/img/FD101154.png "Click to enlarge")
(3E)-N,N-Dimethyl-3-[2-(Trifluoromethyl)Thioxanthen-9-Ylidene]Propan-1-Amine Chloride
CAS: 37028-28-7
Ref. 3D-FD101154
| Undefined size | To inquire |
Product Information
- (3E)-N,N-dimethyl-3-[2-(trifluoromethyl)-9H-thioxanthen-9-ylidene]propan-1-amine
- (3E)-N,N-dimethyl-3-[2-(trifluoromethyl)-9H-thioxanthen-9-ylidene]propan-1-amine hydrochloride
- 1-Propanamine, N,N-dimethyl-3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)-,hydrochloride, (E)- (9CI)
- 1-Propanamine, N,N-dimethyl-3-[2-(trifluoromethyl)-9H-thioxanthen-9-ylidene]-, hydrochloride, (3E)-
- 1-Propanamine, N,N-dimethyl-3-[2-(trifluoromethyl)-9H-thioxanthen-9-ylidene]-, hydrochloride, (E)-
- 9H-Thioxanthene, 1-propanamine deriv.
- N 796 (trans)
- Nsc 170994
- Skf 10812
- Thioxanthene, 9-(3-(dimethylamino)propylidene)-2-trifluoromethyl-, hydrochloride, (E)-
- See more synonyms
- trans-9-(3-(Dimethylamino)propylidene)-2-trifluoromethyl-, thioxanthene, hydrochloride
(3E)-N,N-Dimethyl-3-[2-(Trifluoromethyl)Thioxanthen-9-Ylidene]Propan-1-Amine Chloride is a chlorinated substituted thioxanthene. It is used as an analog of clozapine, with similar but not identical effects. The cytotoxicity of (3E)-N,N-Dimethyl-3-[2-(Trifluoromethyl)Thioxanthen-9-Ylidene]Propan-1-Amine Chloride to rat liver cells in vitro was higher than that of clozapine or other analogs. The mechanism of action may be due to the ability of (3E)-N,N-Dimethyl-3-[2-(Trifluoromethyl)Thioxanthen-9-Ylidene]Propan-1-Amine Chloride
Chemical properties
Technical inquiry about: 3D-FD101154 (3E)-N,N-Dimethyl-3-[2-(Trifluoromethyl)Thioxanthen-9-Ylidene]Propan-1-Amine Chloride
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
